Intensity Therapeutics (INTS) director awarded 5,500 stock options at $4.90
Rhea-AI Filing Summary
Intensity Therapeutics, Inc. reported that director Emer Leahy received a grant of stock options covering 5,500 shares of common stock at an exercise price of $4.90 per share. The options vest in four equal annual installments beginning July 16, 2026, subject to continued service, and expire July 16, 2036, leaving Leahy with options on 5,500 shares in total.
Positive
- None.
Negative
- None.
Insider Trade Summary
1 transaction reported
Mixed
1 txn
Insider
Leahy Emer
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (right to buy Common Stock) F1 | 5,500 | $0.00 | $0.00 |
Holdings After Transaction:
Stock Option (right to buy Common Stock) — 5,500 shares (Direct)
Footnotes (1)
- F1. This option will vest, subject to the individual's continued service with Intensity Therapeutics, Inc., in four, equal, annual installments, beginning on July 16, 2026.
Key Figures
Options Granted: 5,500 shares
Exercise Price: $4.90 per share
Underlying Shares: 5,500 shares
+3 more
6 metrics
Options Granted
5,500 shares
Stock options granted to director Emer Leahy
Exercise Price
$4.90 per share
Exercise price of the stock option grant
Underlying Shares
5,500 shares
Common stock underlying the option grant
Vesting Start Date
July 16, 2026
First vesting date, in four equal annual installments
Expiration Date
July 16, 2036
Expiration of the stock options
Options Held After Grant
5,500 shares
Total derivative holdings following this transaction
Key Terms
Stock Option (right to buy Common Stock), exercise price, vest, expiration date
4 terms
Stock Option (right to buy Common Stock) financial
"security_title: Stock Option (right to buy Common Stock)"
exercise price financial
"conversion_or_exercise_price of $4.9000 per share"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
vest financial
"This option will vest in four, equal, annual installments"
A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.
expiration date financial
"expiration_date reported as 2036-07-16 for the option"
The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What insider transaction did Intensity Therapeutics (INTS) report for Emer Leahy?
Emer Leahy received a grant of stock options for 5,500 shares of Intensity Therapeutics common stock at an exercise price of $4.90 per share. The award is a compensation grant, not an open-market trade, and will vest over four years starting July 16, 2026.
What is the exercise price and term of Emer Leahy's Intensity Therapeutics (INTS) stock options?
The options have an exercise price of $4.90 per share and an expiration date of July 16, 2036. This gives a long-dated right to buy Intensity Therapeutics common stock at that price if the options vest and are later exercised.
When do Emer Leahy's Intensity Therapeutics (INTS) stock options vest?
The options vest in four equal annual installments beginning on July 16, 2026, as long as Leahy continues serving with Intensity Therapeutics. Each year, one quarter of the 5,500 options becomes exercisable until the full grant is vested.